Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras PharmaphorumAmgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.OncologyRead full story pharminent July 9, 2026 (Last updated: July 10, 2026) Pharmaphorum Amgen’s Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE. Oncology Read full story Post navigation Previous: UK first in Europe to clear Boehringer’s IPF drug JascaydNext: FDA freezes CRL trove as ‘radical transparency’ push hits speedbump Related Stories Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026 Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026